DBV TECHNOLOGIES News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.11.20	DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020 (GlobeNewswire)
09.11.20	DBV Technologies to Participate in Upcoming Investor Conferences (GlobeNewswire)
02.11.20	DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency (GlobeNewswire)
30.10.20	DBV Technologies Reports September 30, 2020 Cash Position (GlobeNewswire)
08.10.20	Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020 (GlobeNewswire)
15.09.20	Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2020 (GlobeNewswire)
09.09.20	DBV Technologies Announces Leadership Changes (GlobeNewswire)
02.09.20	DBV Technologies to Participate in Multiple September Investor Conferences (GlobeNewswire)
12.08.20	Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020 (GlobeNewswire)
04.08.20	DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years (GlobeNewswire)
31.07.20	DBV Technologies Reports First Half 2020 Financial Results (GlobeNewswire)
20.07.20	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
15.07.20	Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2020 (GlobeNewswire)
10.07.20	DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology (GlobeNewswire)
26.06.20	DBV Technologies Provides Operational and Business Update (GlobeNewswire)
11.06.20	Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020 (GlobeNewswire)
04.06.20	DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020 (GlobeNewswire)
02.06.20	DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference (GlobeNewswire)
12.05.20	Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020 (GlobeNewswire)
30.04.20	DBV Technologies Reports March 31, 2020 Cash Position (GlobeNewswire)
20.04.20	DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting (GlobeNewswire)
15.04.20	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
10.04.20	Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 Pandemic (GlobeNewswire)
30.03.20	Ordinary and Extraordinary General Meeting of April 20, 2020 (GlobeNewswire)
26.03.20	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
20.03.20	DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F (GlobeNewswire)
17.03.20	Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020 (GlobeNewswire)
16.03.20	DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years (GlobeNewswire)
04.03.20	DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update (GlobeNewswire)
04.03.20	DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering (GlobeNewswire)
02.03.20	DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (A (GlobeNewswire)
24.02.20	DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 (GlobeNewswire)
21.02.20	DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children (GlobeNewswire)
10.02.20	DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference (GlobeNewswire)
07.02.20	Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020 (GlobeNewswire)
06.02.20	DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer (GlobeNewswire)
04.02.20	DBV Technologies Announces Closing of Global Offering (GlobeNewswire)
30.01.20	DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (GlobeNewswire)
29.01.20	DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position (GlobeNewswire)
15.01.20	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
14.01.20	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
08.01.20	DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy (GlobeNewswire)
02.01.20	DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer (GlobeNewswire)
10.12.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
19.11.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
05.11.19	DBV Technologies to Present at the Stifel 2019 Healthcare Conference (GlobeNewswire)
29.10.19	Ausblick: DBV TECHNOLOGIES stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
24.10.19	DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019 (GlobeNewswire)
16.10.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
15.10.19	DBV Technologies Announces Closing of Global Offering (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu DBV TECHNOLOGIES

Aktien Top/Flop

Meistgelesene Nachrichten